Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (171-180 of 191) with videos related to

Pageof 20
Sort By:
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Journal for Immunotherapy of Cancer|March 6, 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
The New England Journal of Medicine|September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Reviews. Nephrology|December 9, 2025
The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupAmanda DeMauro Renaghan, Marlies Ostermann, Claudio Ronco, et al.
Pageof 20

Showing results (171-180 of 191) with videos related to

Sort By:
Pageof 20
Nature Medicine|August 17, 2023
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trialAri VanderWalde, Shay L Bellasea, Kari L Kendra, et al.
Journal for Immunotherapy of Cancer|March 6, 2024
Clinical outcomes and safety of immune checkpoint inhibitors in patients with solid tumors and paraneoplastic syndromesAmin H Nassar, Talal El Zarif, Ahmed Bilal Khalid, et al.
Journal for Immunotherapy of Cancer|October 15, 2025
Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitorsLing Zhu, Yee-Ming M Cheung, Cherie Chiang, et al.
The Lancet. Oncology|January 16, 2022
Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trialJonathan D Schoenfeld, Anita Giobbie-Hurder, Srinika Ranasinghe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2021
Correction: A Randomized Trial of Combined PD-L1 and CTLA-4 Inhibition with Targeted Low-dose or Hypofractionated Radiation for Patients with Metastatic Colorectal CancerArta M Monjazeb, Anita Giobbie-Hurder, Ana Lako, et al.
The New England Journal of Medicine|September 16, 2024
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B Apolo, Karla V Ballman, Guru Sonpavde, et al.
Journal for Immunotherapy of Cancer|February 11, 2026
DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervixYoung Kwang Chae, Megan Othus, Sandip P Patel, et al.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Reviews. Nephrology|December 9, 2025
The nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupAmanda DeMauro Renaghan, Marlies Ostermann, Claudio Ronco, et al.
Pageof 20